Current Environment: Production

Warning

An important message to our patients and their caregivers.

We are here for you. Read more

Research & Innovation | Overview

In the setting of one of the world’s most extensive pediatric research hospitals, we apply a science-driven approach to sickle cell disease. Dana-Farber/Boston Children's was one of the original National Institutes of Health-funded comprehensive sickle cell centers in the United States, and a site for the Sickle Cell Disease Clinical Research Network. Our researchers conduct clinical and laboratory studies to increase and enhance knowledge of sickle cell disorders and treatment. Keeping abreast of current basic scientific research, its translation to clinical care, and advising families and referring physicians about available clinical trials are among our highest priorities.

In the 1980s, our physicians were the first to recognize the potential of hydroxyurea to treat sickle cell disease and to use the medication in children. Today, our researchers continue to work on developing new methods of diagnosing and treating sickle cell disease, including stem cell research, stem cell transplantation, and gene therapy.

Search for current sickle cell disease clinical trials.

Talk to Lesley

If this is a medical emergency, please dial 9-1-1. This application should not be used in an emergency. This chat is being transmitted via a secure connection.

Hi! My name is Lesley. I am a virtual agent programmed to help you. If you would like to speak to a live agent, please call 617-355-6000 or click here to log into your MyChildrens portal.

For questions regarding an upcoming appointment, doctor notes, or specific questions related to symptoms or a diagnosis, please call the department of clinic directly.

Quick links:

- Global Services
- Find a Doctor
- Find a Location
- Programs and Services
- Conditions and Treatments
- Request an Appointment